Go Pro
→ Where to Put $100 Before Trump's New Tech Law Rolls Out (From Brownstone Research) (Ad)tc pixel Free YDES Stock Alerts

YD Bio (YDES) Financials

YD Bio logo
$2.23 +0.09 (+4.21%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$2.21 -0.02 (-0.90%)
As of 07/10/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for YD Bio

Annual Income Statements for YD Bio

This table shows YD Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.01 -1.41 -8.31
Consolidated Net Income / (Loss)		 0.01 -1.41 -8.31
Net Income / (Loss) Continuing Operations		 0.01 -1.41 -8.31
Total Pre-Tax Income 		0.02 -1.39 -8.31
Total Operating Income		 -0.01 -1.46 -5.27
Total Gross Profit		 0.15 0.16 0.17
Total Revenue		 0.35 0.51 0.60
Operating Revenue		 0.35 0.51 0.60
Total Cost of Revenue		 0.20 0.36 0.43
Operating Cost of Revenue		 0.20 0.36 0.43
Total Operating Expenses		 0.16 1.62 5.44
Selling, General & Admin Expense		 0.15 1.12 3.66
Marketing Expense		 0.01 0.00 0.17
Research & Development Expense		 0.00 0.49 1.60
Other Operating Expenses / (Income)		 0.00 -0.00 0.00
Total Other Income / (Expense), net		 0.03 0.08 -3.04
Interest Expense		 0.00 0.00 0.00
Interest & Investment Income		 0.00 0.01 0.08
Other Income / (Expense), net		 0.03 0.06 -3.12
Income Tax Expense		 0.00 0.03 -0.00
Basic Earnings per Share		 $0.00 ($0.02) ($0.12)
Weighted Average Basic Shares Outstanding		 64.73M 64.73M 66.72M
Diluted Earnings per Share		 $0.00 ($0.02) ($0.12)
Weighted Average Diluted Shares Outstanding		 64.73M 64.73M 66.72M
Weighted Average Basic & Diluted Shares Outstanding		 - - 70.79M

Quarterly Income Statements for YD Bio

No quarterly income statements for YD Bio are available.

Annual Cash Flow Statements for YD Bio

This table details how cash moves in and out of YD Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.06 3.05 2.88
Net Cash From Operating Activities		 -0.06 -1.22 -6.60
Net Cash From Continuing Operating Activities		 -0.06 -1.22 -6.60
Net Income / (Loss) Continuing Operations		 0.01 -1.41 -8.31
Consolidated Net Income / (Loss)		 0.01 -1.41 -8.31
Depreciation Expense		 0.00 0.01 0.02
Amortization Expense		 0.00 0.09 0.19
Non-Cash Adjustments To Reconcile Net Income		 0.00 0.04 3.19
Changes in Operating Assets and Liabilities, net		 -0.08 0.05 -1.69
Net Cash From Investing Activities		 -0.00 -2.90 -1.44
Net Cash From Continuing Investing Activities		 -0.00 -2.90 -1.27
Purchase of Property, Plant & Equipment		 -0.00 -0.07 -1.44
Acquisitions		 0.00 -2.84 0.00
Divestitures		 0.00 0.00 0.17
Sale and/or Maturity of Investments		 0.00 0.01 0.00
Net Cash From Financing Activities		 0.11 7.11 11
Net Cash From Continuing Financing Activities		 0.11 7.11 11
Repayment of Debt		 0.06 -0.13 0.00
Repurchase of Common Equity		 0.00 -0.61 -3.22
Issuance of Common Equity		 0.05 7.86 13
Other Financing Activities, net		 0.00 0.00 0.72
Effect of Exchange Rate Changes		 - - 0.04
Cash Interest Paid		 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00

Quarterly Cash Flow Statements for YD Bio

No quarterly cash flow statements for YD Bio are available.

Annual Balance Sheets for YD Bio

This table presents YD Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025
Period end date 12/31/2024 12/31/2025
Total Assets		 6.86 14
Total Current Assets		 3.47 9.67
Cash & Equivalents		 3.13 6.01
Accounts Receivable		 0.10 0.46
Inventories, net		 0.04 1.88
Prepaid Expenses		 0.19 1.32
Other Current Assets		 0.02 0.01
Plant, Property, & Equipment, net		 0.06 0.06
Total Noncurrent Assets		 3.31 4.04
Intangible Assets		 2.68 2.61
Other Noncurrent Operating Assets		 0.63 1.43
Total Liabilities & Shareholders' Equity		 6.86 14
Total Liabilities		 0.27 17
Total Current Liabilities		 0.26 1.64
Accounts Payable		 0.21 0.85
Accrued Expenses		 0.00 0.00
Other Current Liabilities		 0.05 0.79
Total Noncurrent Liabilities		 0.01 15
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 0.00
Other Noncurrent Operating Liabilities		 0.01 15
Commitments & Contingencies		 0.00 0.00
Total Equity & Noncontrolling Interests		 6.59 -2.86
Total Preferred & Common Equity		 6.59 -2.86
Total Common Equity		 6.59 -2.86
Common Stock		 8.47 7.17
Retained Earnings		 -1.93 -10
Accumulated Other Comprehensive Income / (Loss)		 0.05 0.21

Quarterly Balance Sheets for YD Bio

No quarterly balance sheets for YD Bio are available.

Annual Metrics And Ratios for YD Bio

This table displays calculated financial ratios and metrics derived from YD Bio's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00
Growth Metrics		 - - -
Revenue Growth		 0.00% 45.76% 16.94%
EBITDA Growth		 0.00% -5,988.05% -533.01%
EBIT Growth		 0.00% -7,265.27% -500.57%
NOPAT Growth		 0.00% -13,427.08% -260.60%
Net Income Growth		 0.00% -10,509.73% -488.80%
EPS Growth		 0.00% 0.00% -500.00%
Operating Cash Flow Growth		 0.00% -2,096.81% -439.53%
Free Cash Flow Firm Growth		 0.00% 0.00% 292.60%
Invested Capital Growth		 0.00% 0.00% -356.32%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 43.83% 30.44% 28.05%
EBITDA Margin		 6.27% -253.31% -1,371.18%
Operating Margin		 -2.81% -286.45% -883.31%
EBIT Margin		 5.57% -273.83% -1,406.30%
Profit (Net Income) Margin		 3.87% -276.58% -1,392.61%
Tax Burden Percent		 76.83% 101.81% 99.98%
Interest Burden Percent		 90.49% 99.21% 99.04%
Effective Tax Rate		 23.17% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -59.19% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -34.40% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 16.35% 0.00%
Return on Equity (ROE)		 0.00% -42.84% -445.10%
Cash Return on Invested Capital (CROIC)		 0.00% -259.19% 0.00%
Operating Return on Assets (OROA)		 0.00% -20.36% -81.31%
Return on Assets (ROA)		 0.00% -20.56% -80.52%
Return on Common Equity (ROCE)		 0.00% -42.84% -445.10%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.01 -1.02 -3.69
NOPAT Margin		 -2.16% -200.52% -618.31%
Net Nonoperating Expense Percent (NNEP)		 0.00% -24.79% -101.12%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.53% 129.22%
Cost of Revenue to Revenue		 56.18% 69.56% 71.95%
SG&A Expenses to Revenue		 43.72% 220.33% 613.78%
R&D to Revenue		 0.00% 96.28% 268.43%
Operating Expenses to Revenue		 46.64% 316.89% 911.36%
Earnings before Interest and Taxes (EBIT)		 0.02 -1.40 -8.39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.02 -1.29 -8.18
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 1,362.74
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1,352.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 93.53
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 0.00 -0.48 -2.45
Leverage Ratio		 0.00 1.04 5.53
Compound Leverage Factor		 0.00 1.03 5.47
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 27.03
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 0.00 13.18 5.88
Quick Ratio		 0.00 12.30 3.93
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -4.48 8.63
Operating Cash Flow to CapEx		 -19,192.07% -1,632.11% -458.10%
Free Cash Flow to Firm to Interest Expense		 0.00 -5,804.79 0.00
Operating Cash Flow to Interest Expense		 -25.96 -1,583.78 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -26.09 -1,680.82 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.07 0.06
Accounts Receivable Turnover		 0.00 4.93 2.12
Inventory Turnover		 0.00 9.51 0.45
Fixed Asset Turnover		 0.00 7.93 9.65
Accounts Payable Turnover		 0.00 1.70 0.81
Days Sales Outstanding (DSO)		 0.00 74.03 172.01
Days Inventory Outstanding (DIO)		 0.00 38.39 814.68
Days Payable Outstanding (DPO)		 0.00 215.12 450.66
Cash Conversion Cycle (CCC)		 0.00 -102.70 536.03
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 3.46 -8.86
Invested Capital Turnover		 0.00 0.30 -0.22
Increase / (Decrease) in Invested Capital		 0.00 3.46 -12
Enterprise Value (EV)		 0.00 0.00 807
Market Capitalization		 0.00 0.00 813
Book Value per Share		 $0.00 $0.10 ($0.04)
Tangible Book Value per Share		 $0.00 $0.06 ($0.08)
Total Capital		 0.00 6.59 -2.86
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 0.00 -3.13 -6.01
Capital Expenditures (CapEx)		 0.00 0.07 1.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.07 2.02
Debt-free Net Working Capital (DFNWC)		 0.00 3.20 8.03
Net Working Capital (NWC)		 0.00 3.20 8.03
Net Nonoperating Expense (NNE)		 -0.02 0.39 4.62
Net Nonoperating Obligations (NNO)		 0.00 -3.13 -6.01
Total Depreciation and Amortization (D&A)		 0.00 0.10 0.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 14.21% 338.29%
Debt-free Net Working Capital to Revenue		 0.00% 627.95% 1,344.90%
Net Working Capital to Revenue		 0.00% 627.95% 1,344.90%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.12)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 66.72M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 66.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 70.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.01 -1.02 -3.69
Normalized NOPAT Margin		 -2.16% -200.52% -618.31%
Pre Tax Income Margin		 5.04% -271.67% -1,392.86%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 9.10 -1,810.25 0.00
NOPAT to Interest Expense		 -3.53 -1,325.58 0.00
EBIT Less CapEx to Interest Expense		 8.96 -1,907.29 0.00
NOPAT Less CapEx to Interest Expense		 -3.66 -1,422.62 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -43.51% -38.74%

Quarterly Metrics And Ratios for YD Bio

No quarterly metrics and ratios for YD Bio are available.


Financials Breakdown Chart

YD Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, YD Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

YD Bio's net income appears to be on an upward trend, with a most recent value of -$8.31 million in 2025, falling from $13.56 thousand in 2023. The previous period was -$1.41 million in 2024. Check out YD Bio's forecast to explore projected trends and price targets.

YD Bio's total operating income in 2025 was -$5.27 million, based on the following breakdown:
  • Total Gross Profit: $167.41 thousand
  • Total Operating Expenses: $5.44 million

Over the last 2 years, YD Bio's total revenue changed from $350.13 thousand in 2023 to $596.82 thousand in 2025, a change of 70.5%.

YD Bio's total liabilities were at $16.64 million at the end of 2025, a 5,971.6% increase from 2024, and a 5,971.6% increase since 2024.

In the past 1 years, YD Bio's cash and equivalents has ranged from $3.13 million in 2024 to $6.01 million in 2025, and is currently $6.01 million as of their latest financial filing in 2025.

Over the last 2 years, YD Bio's book value per share changed from 0.00 in 2023 to -0.04 in 2025, a change of -4.3%.



Financial statements for NASDAQ:YDES last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Buy the “unseen winner of the AI race” before July 22
Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...
Chaikin Analytics | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s New Currency (BUY NOW)
Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...
InvestorPlace | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel